Singapore’s National Platform for
Diagnostics Development

DxD Hub is an end-to-end productisation partner dedicated to transforming the MedTech landscape in Singapore, through innovative solutions from both local and regional partners. We expedite diagnostics and digital health product development by enabling validation, registration, and deployment of solutions that improve patient care and save lives.

We are a high-throughput productisation platform, whose strengths consists of the cross-cutting, multidisciplinary product development specialists from all walks of life. These specialists work with both public and private partners in different areas across the product development life cycle, including: product development, pilot production, quality assurance, building business cases, obtaining regulatory clearance, gaining clinical adoption, and transferring customised manufacturing processes and technologies to companies for manufacturing scale-ups. 

The Journey So Far

NOV 2013

DxD Hub was launched by then-Second Minister for Trade and Industry, Mr S Iswaran. 

Jan 2015

DxD Hub attained ISO 13485 IVD design and development certification.

May 2017

Laennec® (co-developed with HistoIndex and SGH) is the world’s first stain-free digital pathology imaging system approved for clinical diagnosis of liver diseases. 


DxD Hub’s Clinical Laboratory (ClinLab) is established to pilot the deployment of innovative tests developed by DxD Hub, or its strategic partners in Singapore and the region. 

May 2019

ASTROCLEAR (co-developed with MiRXES, SGCC, NUH, and TTSH), approved as a Class 3 IVD, is the world’s first miRNA blood test for early detection of gastric cancer. 

Jul 2019

Tissue PD-L1 Triplex™ (co-developed with Lucence, IMCB and SGH) is the first immunohistochemistry tissue
test for three PD-L1 markers.

Feb 2020

Fortitude 2.0 (co-developed and launched with EDDC, BII, TTSH and licensed to MiRXES) is the first test kit for COVID-19 management in Singapore.

May 2020

ASSURE® (co-developed with MP Biomedicals and NUH) is an antibody detection test kit for COVID-19 virus.

May 2020

cPass™ (co-developed with Duke-NUS and GenScript) is a novel surrogate test for COVID-19 viral neutralisation antibodies.

May 2020

Respiree Monitor (co-developed with Respiree and SBIC) is a wearable device that can predict worsening conditions in COVID-19 patients.

Jun 2020

RESOLUTE 2.0 (co-developed with DSO) is a one-step RT-PCR test for COVID-19 eliminating the need for an additional RNA extraction kit.

Jun 2020

RAVE (co-developed with AMT, ARTC, and SIMTech) was developed as an automated lab system that runs RESOLUTE 2.0 in half the time.

26th Oct 2021

The RESOLUTE 2.0 team is awarded the Defence Technology Prize by the Ministry of Defence, in recognition of their contributions towards enhancing Singapore’s defence capabilities.

14th Sept 2021

Tissue500™ is made commercially available, and is showcased at both local and regional conferences such as the Frontier in Cancer Science 2021 in Singapore, and the United States & Canadian Academy of Pathology (USCAP) 2022 Annual Meeting.

Mar 2022 


4th Apr 2022

The National Research Foundation approves the Digital Health Accelerator Funding Initiative

May 2022

DxD Hub’s ClinLab receives CAP Accreditation.

6th July 2022

The RESOLUTE 2.0 team is awarded the Exemplary Innovator Award at the 2022 Public Sector Transformation COVID-19 Awards 2022.

April 2023

DxD Hub launches the DxD Hub Innovation & Enterprise Fellowship Programme (IFP).


27th July 2023

Digital Health Accelerator Launch Event is attended by over 100 attendees, with key stakeholders from the clusters, Ministry of Health, A*STAR leadership, DxD Hub advisors, and digital health practitioners.